title: Anti-HLA antibody profile of Turkish patients with end-stage renal disease.
abstract: Exposure to human leukocyte antigens (HLA) via blood transfusions, pregnancies, and previous transplantations can result in anti-HLA antibody production. The presence of anti-HLA antibodies in recipient sera before transplantation is an important risk factor. To demonstrate the anti-HLA antibody status of Turkish end-stage renal disease (ESRD) patients, 674 patients (mean age, 40.35 +/- 13.15 years; female/male, 328/346) were enrolled into the study. Anti-HLA antibody screening and identification tests were performed using an enzyme-linked immunosorbent assay (ELISA) method. The panel-reactive antibody (PRA)-negative group consisted of 564 (83.6%) and the PRA-positive group consisted of 110 (17.3%) patients. Of the 110 (17.3%) PRA-positive patients, 43 (6.4%) were class I (+) and class II (-); 19 (2.8%) were class I (-) and class II (+); 48 (7.1%) were both class I and II (+). The most frequent antibodies were directed against the A2 crossreactive group (CREG) and the A10 CREG with less frequent reactions against the B7 CREG, indicating antibodies to both frequent (members of A2 CREG) and relatively rare (members of A10 CREG and B7 CREG antigens). These data also suggested that some antibodies occur at greater than expected frequency because of shared epitopes. Our findings confirmed the significant correlation between female gender, pregnancy, failed graft history, long dialysis duration, and blood transfusions with PRA positivity (P < .05).
authors.affiliation: Department of Medical Biology, Istanbul University, Istanbul, Turkey.
authors.forename: G E
authors.initials: GE
authors.lastname: Karahan
authors.forename: Y
authors.initials: Y
authors.lastname: Seyhun
authors.forename: F
authors.initials: F
authors.lastname: Oguz
authors.forename: C
authors.initials: C
authors.lastname: Kekik
authors.forename: E
authors.initials: E
authors.lastname: Onal
authors.forename: Y
authors.initials: Y
authors.lastname: Caliskan
authors.forename: H
authors.initials: H
authors.lastname: Bakkaloglu
authors.forename: H
authors.initials: H
authors.lastname: Yazici
authors.forename: A
authors.initials: A
authors.lastname: Turkmen
authors.forename: A E
authors.initials: AE
authors.lastname: Aydin
authors.forename: M S
authors.initials: MS
authors.lastname: Sever
authors.forename: U
authors.initials: U
authors.lastname: Eldegez
authors.forename: M N
authors.initials: MN
authors.lastname: Carin
mesh_terms: D000017:ABO Blood-Group System; D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006680:HLA Antigens / Q000235:genetics / Q000276:immunology*; D006681:HLA-D Antigens / Q000276:immunology; D006684:HLA-DR Antigens / Q000276:immunology; D059811:HLA-DRB1 Chains; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D006801:Humans; D007676:Kidney Failure, Chronic / Q000276:immunology*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011247:Pregnancy; D006435:Renal Dialysis; D014421:Turkey; D014850:Waiting Lists
chemical_list: D000017:ABO Blood-Group System; D006680:HLA Antigens; D006681:HLA-D Antigens; D006684:HLA-DR Antigens; D059811:HLA-DRB1 Chains; D015395:Histocompatibility Antigens Class I